Business Context and Reporting Period
Company: ACME UNITED CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: The Company manufactures and distributes consumer products. Sales are seasonal, typically stronger in the second and third quarters due to the back-to-school season. In March 1999, the Company sold its medical business segment to Medical Action Industries, Inc.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1998 |
|---|---|---|---|
| Net Sales | $9,327,000 | $26,710,000 | $29,395,000 |
| Gross Profit | $2,236,000 (24.0%) | $6,123,000 (23.0%) | $6,699,000 (22.8%) |
| Net Income | $136,000 | $2,018,000 | $97,000 |
| Income from Continuing Ops | $136,000 | ($281,000) | ($658,000) |
| EPS (Net Income) | $0.04 | $0.60 | $0.03 |
| Cash and Equivalents | $0 | $0 (End of Period) | $331,000 (End of Period) |
| Total Debt | $9,331,000 | $9,331,000 | $15,326,000 |
| Working Capital | $1,075,000 | $1,075,000 | $3,616,000 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales for the nine months ended September 30, 1999, decreased 9% to $26.7 million compared to $29.4 million in 1998. The third quarter saw a 12% decline. This was driven by the sale of the medical business, inventory build-up for the sale, and weaker international sales (down 26% in Q3) due to economic slowdowns in the UK and product rationalization in Canada.
- Profitability Improvement: Despite lower sales, gross margins improved. The third quarter gross margin rose to 24.0% from 22.2% in the prior year, aided by product sourcing alternatives and the discontinuation of lower-margin products in Canada.
- Debt Reduction: Total debt decreased by approximately $6.0 million year-over-year. Proceeds from the sale of the medical business ($8.2 million) were used to pay down $6.8 million of outstanding debt.
- Cash Flow: Net cash used by operating activities was $2.75 million for the nine months ended September 30, 1999, compared to $1.61 million in the prior year. However, investing activities provided $7.9 million due to the sale of the medical division.
- Discontinued Operations: The nine-month net income of $2.0 million includes a $2.1 million gain on the sale of the medical business. Without this gain, the Company reported a loss from continuing operations of $281,000.
Guidance, Outlook, Risks, and Contingencies
- Liquidity and Debt Refinancing: The Company faces a critical liquidity situation. Approximately $7.9 million of debt is classified as current with a maturity date of April 30, 2000. Management is negotiating to refinance these arrangements to extend the maturity beyond December 31, 2000. The filing explicitly states that without adequate debt financing, the Company would be unable to fund obligations as they become due.
- Outlook: Management expects to continue consolidating product sourcing from Asia to improve margins. Capital expenditures for the next 12 months are expected to be under $250,000.
- Year 2000 Compliance: The Company has completed the assessment and modification phases of its Year 2000 compliance program, with a goal of completion by November 1999. Estimated total costs are $125,000.
- Legal and Environmental: The Company is involved in environmental matters and lawsuits regarding latex products (distributed but not manufactured). Management believes these will not have a material adverse impact on financial position.
- Covenants: The Company is currently in compliance with debt covenants regarding tangible net worth and debt service coverage ratios, though substantially all assets are pledged as collateral.
Investor Verification Checklist
- Debt Refinancing Status: Verify the outcome of negotiations to extend the maturity of the $7.9 million current debt due April 30, 2000.
- Liquidity Position: Confirm the Company's ability to meet short-term obligations given the $0 cash balance and reliance on future financing.
- Continuing Operations Viability: Assess the sustainability of the core business, which reported a loss from continuing operations of $281,000 for the nine-month period, excluding the one-time gain from the medical division sale.
- International Sales Trends: Monitor the recovery of international sales, particularly in the UK and Canada, which contributed significantly to the revenue decline.
- Year 2000 Costs: Track actual costs incurred for Year 2000 compliance against the estimated $125,000 budget.